secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2026-05-14T12:09:20+00:00
Accession:  0001193125-26-222879
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Benitec Q3 net loss $0.24/shr, cash $184.8M; BB-301 clinical progress continues
-------------------------------------------------------------------------------

- Net loss $11.9M ($0.24/shr) vs $14.5M ($0.38/shr) in prior year quarter; total expenses $13.6M.
- Cash and equivalents $184.8M, well-capitalized to advance BB-301 through pivotal study.
- Cohort 1 low-dose BB-301 shows durable responses at 12-24 months; Cohort 2 high dose safely treating patients.
- Oral presentation at ASGCT 2026 on May 15; FDA engagement mid-year to formalize pivotal study design.
- Updated BB-301 interim results expected 2H-2026; no treatment-related severe adverse events observed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312526222879/0001193125-26-222879-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312526222879/bntc-20260514.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-222879

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer